Referral Patterns for Patients with Nonalcoholic Fatty Liver Disease
暂无分享,去创建一个
[1] K. Cusi,et al. A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis. , 2020, The New England journal of medicine.
[2] J. Holst,et al. Nonalcoholic Fatty Liver Disease Impairs the Liver–Alpha Cell Axis Independent of Hepatic Inflammation and Fibrosis , 2020, Hepatology communications.
[3] B. Nordestgaard,et al. High Risk of Fatty Liver Disease Amplifies the Alanine Transaminase–Lowering Effect of a HSD17B13 Variant , 2020, Hepatology.
[4] G. Tarantino,et al. Nonalcoholic Fatty Liver Disease: A Challenge from Mechanisms to Therapy , 2019, Journal of clinical medicine.
[5] V. Wong,et al. Reduced Patient-Reported Outcome Scores Associate with Level of Fibrosis in Patients with Nonalcoholic Steatohepatitis. , 2019, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[6] C. Faselis,et al. NAFLD-NASH: An Under-Recognized Epidemic. , 2017, Current vascular pharmacology.
[7] L. Henry,et al. NAFLD AND NASH: Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention , 2018 .
[8] R. Wong,et al. Significant burden of nonalcoholic fatty liver disease with advanced fibrosis in the US: a cross‐sectional analysis of 2011‐2014 National Health and Nutrition Examination Survey , 2017, Alimentary pharmacology & therapeutics.
[9] S. Hunt,et al. A disease‐specific quality of life instrument for non‐alcoholic fatty liver disease and non‐alcoholic steatohepatitis: CLDQ‐NAFLD , 2017, Liver international : official journal of the International Association for the Study of the Liver.
[10] T. Card,et al. Economic evaluation of a community-based diagnostic pathway to stratify adults for non-alcoholic fatty liver disease: a Markov model informed by a feasibility study , 2017, BMJ Open.
[11] M. Kumar,et al. Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis. , 2017, Journal of hepatology.
[12] E. Disse,et al. EASL–EASD–EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease in severely obese people: do they lead to over-referral? , 2017, Diabetologia.
[13] C. Day,et al. Non-alcoholic fatty liver disease (NAFLD): summary of NICE guidance , 2016, British Medical Journal.
[14] L. Henry,et al. Global epidemiology of nonalcoholic fatty liver disease—Meta‐analytic assessment of prevalence, incidence, and outcomes , 2016, Hepatology.
[15] Z. Younossi,et al. Non-alcoholic Fatty Liver Disease (NAFLD) is associated with impairment of Health Related Quality of Life (HRQOL) , 2016, Health and Quality of Life Outcomes.
[16] T. Vilsbøll,et al. Diabetic and nondiabetic patients with nonalcoholic fatty liver disease have an impaired incretin effect and fasting hyperglucagonaemia , 2016, Journal of internal medicine.
[17] European Association for the Study of the Liver,et al. EASL-EASD-EASO Clinical Practice Guidelines for the Management of Non-Alcoholic Fatty Liver Disease , 2016, Obesity Facts.
[18] A. Sanyal,et al. Epidemiology and Natural History of Nonalcoholic Fatty Liver Disease , 2015, Seminars in Liver Disease.
[19] D. S̆timac,et al. Non-alcoholic fatty liver disease and obesity: biochemical, metabolic and clinical presentations. , 2014, World journal of gastroenterology.
[20] Anne Tybjærg-Hansen,et al. Exome-wide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver disease , 2014, Nature Genetics.
[21] Rachel M. Brown,et al. Liraglutide efficacy and action in non-alcoholic steatohepatitis (LEAN): study protocol for a phase II multicentre, double-blinded, randomised, controlled trial , 2013, BMJ Open.
[22] Fabio Nascimbeni,et al. From NAFLD in clinical practice to answers from guidelines. , 2013, Journal of hepatology.
[23] K. Cusi,et al. The Diagnosis and Management of Non-alcoholic Fatty Liver Disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association , 2012, The American Journal of Gastroenterology.
[24] N. Chalasani,et al. Endpoints and clinical trial design for nonalcoholic steatohepatitis , 2011, Hepatology.
[25] R. Anty,et al. Liver fibrogenesis and metabolic factors. , 2011, Clinics and research in hepatology and gastroenterology.
[26] P. Schirmacher,et al. Histopathological diagnosis of non-alcoholic and alcoholic fatty liver disease , 2011, Virchows Archiv.
[27] K. Walsh,et al. Adipokines in inflammation and metabolic disease , 2011, Nature Reviews Immunology.
[28] H. Tilg,et al. Evolution of inflammation in nonalcoholic fatty liver disease: The multiple parallel hits hypothesis , 2010, Hepatology.
[29] A. Kahraman,et al. Obesity Affects the Liver – The Link between Adipocytes and Hepatocytes , 2010, Digestion.
[30] B. Neuschwander‐Tetri,et al. Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease , 2008, Gut.
[31] Laura Herrero,et al. Obesity, inflammation, and insulin resistance. , 2007, Gastroenterology.
[32] O. Cummings,et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease , 2005, Hepatology.
[33] A. McCullough,et al. The clinical features, diagnosis and natural history of nonalcoholic fatty liver disease. , 2004, Clinics in liver disease.